The selected predictors included histological and molecular type of tumor, grading and Ki-67 expression before chemotherapy, TIL density, HER2 status, menopausal status, ER and PR expression, number of chemotherapy cycles and the density of CD123+ DCs. This evidence concerns the gene ESR1 and neoplasm.